Merck is adjusting its Phase 3 strategy for Winrevair after Phase 2 results suggested the most favorable effect occurred at the lowest dose tested. The report says Merck is leaning toward a lower Winrevair dose for a pivotal trial in an uncommon type of heart failure, following a “pretty profound” benefit at the low end. The update comes from the company’s Chief Medical Officer Eliav (as quoted in the excerpt) and reflects how sponsors recalibrate pivotal programs when early signals favor a specific exposure level. The trial design focus is on aligning dose selection ahead of larger efficacy readouts. For the cardiovascular pipeline, the move highlights dose optimization as a core lever in late-stage trial development, especially in rare clinical populations where earlier-phase data can carry outsized weight in setting Phase 3 parameters.